Details for Patent: 11,602,522
Which drugs does patent 11,602,522 protect, and when does it expire?
Patent 11,602,522 protects SOLOSEC and is included in one NDA.
This patent has sixteen patent family members in five countries.
Summary for Patent: 11,602,522
| Title: | Secnidazole for use in the treatment of sexually transmitted infection |
| Abstract: | Method of treating sexually transmitted infection in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above. Pharmaceutical compositions and uses thereof are included herein. |
| Inventor(s): | Helen S. PENTIKIS, David Palling, Carol J. BRAUN, Richard Holl |
| Assignee: | Evofem Biosciences Inc |
| Application Number: | US17/314,833 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; |
Drugs Protected by US Patent 11,602,522
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evofem Inc | SOLOSEC | secnidazole | GRANULE;ORAL | 209363-001 | Sep 15, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF TRICHOMONIASIS IN ADULTS | ⤷ Start Trial | |||
| Evofem Inc | SOLOSEC | secnidazole | GRANULE;ORAL | 209363-001 | Sep 15, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,602,522
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015311674 | ⤷ Start Trial | |||
| Australia | 2018203882 | ⤷ Start Trial | |||
| Australia | 2018217262 | ⤷ Start Trial | |||
| Canada | 2959414 | ⤷ Start Trial | |||
| Canada | 3046521 | ⤷ Start Trial | |||
| Japan | 2017526697 | ⤷ Start Trial | |||
| Japan | 2019056008 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
